Page contentsPage contents Key facts Decision Key facts Active substance tadalafiltamsulosin Therapeutic area Renal and urinary disorders Decision number EMA/PE/0000183373 PIP number EMA/PE/0000183373 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of benign prostatic hyperplasia Route(s) of administration All routes of administration Contact for public enquiries Midas Pharma GmbH E-mail: info@midas-pharma.com Tel. +49 6132 9900 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 06/12/2024 Compliance check done No Decision EMA/PE/0000183373 : EMA decision of 6 December 2024 on the granting of a product specific waiver for tadalafil, tamsulosinAdopted Reference Number: EMADOC-1700519818-1775261 English (EN) (189.16 KB - PDF)First published: 09/12/2025 View Share this page